 Shares of GenMark Diagnostics NASDAQ:GNMK moved lower by 6.81 in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share were up 69.57 over the past year to 0.07, which beat the estimate of 0.09.Revenue of 40,086,000 rose by 118.17 from the same period last year, which beat the estimate of 32,740,000.Guidance Earnings guidance hasnt been issued by the company for now.GenMark Diagnostics hasnt issued any revenue guidance for the time being.Details Of The Call Date: Aug 04, 2020View more earnings on GNMKTime: 04:30 PMET Webcast URL: Action 52-week high: 19.83Companys 52-week low was at 3.36Price action over last quarter: Up 71.87Company Profile GenMark Diagnostics Inc is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. The company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales, and support of instruments and molecular tests based on its proprietary eSensor detection technology. Its operations and assets are in the United States of America.See more from Benzinga Stocks That Hit 52-Week Highs On Wednesday 20 Healthcare Stocks Moving In Wednesdays Pre-Market Session Stocks That Hit 52-Week Highs On MondayC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 